Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Etravirine

FDA-approved product (tablet, oral), marketed as Etravirine, Intelence.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Etravirine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA33.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis44.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Etravirine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Etravirine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers

    NCT01427504 · start 2011-08

    Registered record
    Registry ID
    NCT01427504
    Conditions
    Hepatitis C; HIV
    Interventions
    boceprevir; etravirine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-08
    Completion
    2012-03
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; HIV
    Interventionboceprevir; etravirine
    PhaseNot applicable
    Registry statusCompleted

  • Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine

    NCT01876966 · start 2011-03

    Registered record
    Registry ID
    NCT01876966
    Conditions
    HIV
    Interventions
    Etravirine; Darunavir/ritonavir; artemether/lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-03
    Completion
    2011-07
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionEtravirine; Darunavir/ritonavir; artemether/lumefantrine
    PhasePhase 1
    Registry statusCompleted

  • Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure

    NCT01189695 · start 2010-12

    Registered record
    Registry ID
    NCT01189695
    Conditions
    HIV; AIDS; Lopinavir; Treatment Failure
    Interventions
    Ritonavir-boosted lopinavir; optimized background regimens (OBRs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-12
    Completion
    2013-01
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; AIDS; Lopinavir; Treatment Failure
    InterventionRitonavir-boosted lopinavir; optimized background regimens (OBRs)
    PhasePhase 4
    Registry statusCompleted

  • Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

    NCT01199731 · start 2010-10-05

    Registered record
    Registry ID
    NCT01199731
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    GSK2248761 100 mg once daily; GSK2248761 200 mg once daily; Etravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-10-05
    Completion
    2011-07-19
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionGSK2248761 100 mg once daily; GSK2248761 200 mg once daily; Etravirine
    PhasePhase 2
    Registry statusTerminated

  • The First Failure Study

    NCT01118871 · start 2010-05

    Registered record
    Registry ID
    NCT01118871
    Conditions
    HIV; HIV Infections
    Interventions
    Darunavir, Ritonavir, Truvada; Darunavir, Ritonavir and Etravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-05
    Completion
    2013-05
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV Infections
    InterventionDarunavir, Ritonavir, Truvada; Darunavir, Ritonavir and Etravirine
    PhasePhase 4
    Registry statusTerminated

  • A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients

    NCT01199939 · start 2010-05

    Registered record
    Registry ID
    NCT01199939
    Conditions
    Human Immunodeficiency Virus (HIV)
    Interventions
    Etravirine; Ritonavir; Darunavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-05
    Completion
    2012-10
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV)
    InterventionEtravirine; Ritonavir; Darunavir
    PhasePhase 2
    Registry statusCompleted

  • TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients

    NCT01090648 · start 2010-03

    Registered record
    Registry ID
    NCT01090648
    Conditions
    HIV-Infections
    Interventions
    etravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2010-05
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-Infections
    Interventionetravirine
    PhasePhase 1
    Registry statusCompleted

  • TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

    NCT00980538 · start 2009-12-09

    Registered record
    Registry ID
    NCT00980538
    Conditions
    HIV Infections; HIV-1
    Interventions
    Etravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-12-09
    Completion
    2026-04-08
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; HIV-1
    InterventionEtravirine
    PhasePhase 3
    Registry statusCompleted

  • Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression

    NCT01034917 · start 2009-12

    Registered record
    Registry ID
    NCT01034917
    Conditions
    HIV
    Interventions
    Etravirine 400 mg dissolved in water every 24 hours; Continue with the same antiretroviral regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-12
    Completion
    2011-12
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionEtravirine 400 mg dissolved in water every 24 hours; Continue with the same antiretroviral regimen
    PhasePhase 3
    Registry statusCompleted

  • A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients

    NCT00903682 · start 2009-06

    Registered record
    Registry ID
    NCT00903682
    Conditions
    HIV Infection; HIV; Acquired Immunodeficiency Syndrome
    Interventions
    etravirine (ETR, TMC125); efavirenz (EFV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-01
    Enrolment
    157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; HIV; Acquired Immunodeficiency Syndrome
    Interventionetravirine (ETR, TMC125); efavirenz (EFV)
    PhasePhase 2
    Registry statusCompleted

  • A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

    NCT00855335 · start 2009-04-09

    Registered record
    Registry ID
    NCT00855335
    Conditions
    HIV; HIV Infections; Pregnancy
    Interventions
    Darunavir; Ritonavir; Etravirine; Rilpivirine; Darunavir/Cobicistat (FDC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04-09
    Completion
    2016-08-11
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV Infections; Pregnancy
    InterventionDarunavir; Ritonavir; Etravirine; Rilpivirine +1 more
    PhasePhase 3
    Registry statusCompleted

  • GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

    NCT00867152 · start 2009-04

    Registered record
    Registry ID
    NCT00867152
    Conditions
    Healthy Volunteer
    Interventions
    Darunavir; Etravirine; Ritonavir; Lopinavir/ritonavir; GSK1349572
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04
    Completion
    2009-05
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionDarunavir; Etravirine; Ritonavir; Lopinavir/ritonavir +1 more
    PhasePhase 1
    Registry statusCompleted

  • Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study

    NCT00871234 · start 2009-04

    Registered record
    Registry ID
    NCT00871234
    Conditions
    Endothelial Function; Lipids; Insulin Resistance; Inflammation; HIV Infections
    Interventions
    Etravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04
    Completion
    2010-07
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndothelial Function; Lipids; Insulin Resistance; Inflammation +1 more
    InterventionEtravirine
    PhasePhase 1
    Registry statusCompleted

  • A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

    NCT00823979 · start 2009-03-25

    Registered record
    Registry ID
    NCT00823979
    Conditions
    HIV-1
    Interventions
    UK-453,061 Dose 1; UK-453,061 Dose 2; Etravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-03-25
    Completion
    2012-10-18
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionUK-453,061 Dose 1; UK-453,061 Dose 2; Etravirine
    PhasePhase 2
    Registry statusTerminated

  • Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

    NCT00782301 · start 2009-03

    Registered record
    Registry ID
    NCT00782301
    Conditions
    Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
    Interventions
    maraviroc; etravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2009-03
    Completion
    2010-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
    Interventionmaraviroc; etravirine
    PhasePhase 4
    Registry statusWithdrawn